A number of controversies concerning clinical aspects of hypertension are addressed. These include the need for out-of-the-office blood pressure readings in order not to incorrectly label the many people who have "white-coat" elevations of pressure as being hypertensive.
As this paper is being written, the political leaders of the United States are attempting to reform this nation's very expensive and quite inefficient health care system. Whether they succeed or not, massive changes in this system are already underway, driven by economic forces that are threatening to remove individual physicians from their traditional role as the only ones who decide what, when, and how patients are managed.
Since the treatment of hypertension is today in the US the most frequent indication for visits to physicians, these major changes will certainly alter the management of this disease. At the same time, increasing awareness of the limitations and benefits of antihypertensive therapy are causing reassessments of the recommendations as to when and how patients should be treated. As reviewed by Swales (1), considerable disagreements remain in the guidelines proposed by various expert committees in the recent past but all agree with a number of important fundamentals (Table 1) .
In this paper, I will address some of the areas of continuing controversy about various clinical aspects of hypertension.
The Definition of Hypertension
In a clinical sense, hypertension should be defined as that level of blood pressure wherein the benefits of reduction of the pressure outweigh the costs and adverse effects of doing so (2). On epidemiological grounds, that level could be arbitrarily set almost anywhere since the risks for stroke and coronary disease rise progressively with every increment in blood pressure from as low as 100/60 mmHg (3) (Fig. 1) . On practical grounds, 140/90 mmHg has generally been accepted as the dividing line. Although, as I will explain in the next section, many patients with such a level do not require active drug therapy, the use of 140/90 mmHg to diagnose hypertension can be justified because the overall population risk associated with that level is considerable and nonpharmacological therapy can logically be provided for patients at that level since their use is not associated with adverse risks or excessive costs.
The Need for Out-of-the-Office Readings Whatever level of blood pressure that is used to define hypertension for an individual patient, that level should not be based only upon one or a few readings taken on one or a few office visits. Most people's levels are higher on the first set of readings wherever they are obtained than on subsequent readings (4). An excellent example of the "whitecoat" effect is the experience of the Australian trial wherein thousands of subjects had their pressures taken on two visits one month apart (5). Those with diastolic blood pressure (DBP) above 95 mmHg were entered into the trial, one half receiving active drugs, the other half placebo. Of those given placebo, 48% had an average DBP below 90 mmHg over the ensuing 3 to 4 years of the trial. Clearly those people were not hypertensive to begin with but were labelled as hypertensive on the basis of too few pressure recordings.
The same problem afflicts common clinical prac-tice. Moreover, at least 20% of all patients whose office readings are persistently above 90 mmHg over many years have out-of-the-office readings persistently below 90 mmHg (6). These patients have more than the usual initially higher readings that are seen in almost all people. They have "whitecoat" hypertension, elevated pressures that persist. Although some find that these white-coat hypertensives are not as normal as people who are normotensive both in and out of the office (7), everyone agrees that they do not need active drug therapy but rather advice on nonpharmacological maneuvers that may help prevent subsequent rises in pressure and continued surveillance.
To identify the usual level of pressure and avoid mislabeling and mistreating the white-coat hypertensives, out-of-the-office readings must be obtained on all patients found to have a blood pressure above 140/90, unless their initial readings are so high (above 200/120) or in the presence of advancing target organ damage which mandate immediate therapy.
These out-of-the-office readings can be most rapidly and conveniently obtained by ambulatory blood pressure monitoring (ABPM). However, the continued high financial cost of ABPM precludes its Home blood pressure recordings with inexpensive electronic devices are readily available. They provide reliable data that can be obtained by almost all patients to ascertain their usual range of blood pressure under various conditions. The average of multiple home blood pressure measurements will be about 1015 mmHg lower than those obtained on repeated measurements in the office (9) ( Table 2 ). The data in Table 2 are from 104 newly discovered hypertensives whose readings were taken every 2 weeks in the office and who took multiple readings at home between the third and fourth office reading. Both the tendency for office readings to fall on repeated readings and the usual lower out-of-theoffice readings than office readings are shown.
There are multiple reasons to obtain out-of-theoffice readings (Table 3) . Virtually every patient can and should confirm the presence of usually high pressures before the diagnosis is made and ensure the presence of usually lower pressures before the disease is considered well controlled.
Determining the Need for Drug Therapy
Once the usual range of the blood pressure has been observed and the average level used to establish the presence of hypertension, the practitioner must ascertain the need for institution of therapy. All patients, whether their pressure is only borderline, occasionally elevated, or persistently and significantly elevated should be counseled and strongly urged to use nonpharmacological measures, referred to in the 1993 report of the fifth Joint National Committee (10) as lifestyle modifications ( Table 4 ).
Notice that the top of this list is to stop smoking. For many years, the contribution of smoking-induced rises in blood pressure have been missed for the simple reason that patients have not been allowed to smoke where their pressures are taken. When the blood pressure is recorded while the addicted smoker is smoking, a marked rise in blood pressure is observed (11) (Fig. 2) . This transient pressor effect may be repeated every time the smoker smokes and is likely partly responsible for the cardiovascular events, both strokes and heart attacks, that kill more smokers prematurely than does cancer. Therefore, every hypertensive smoker must be repeatedly told to stop smoking. If they will not, they should be advised to take their blood Table 4 as of proven benefit will, in concert, exert a significant antihypertensive effect. This has been nicely shown in the Treatment of Mild Hypertension Study (TOMHS) (12). TOMHS enrolled 902 mild hypertensives and instructed all to follow a four-step nonpharmacological regimen before randomly allocating the majority to one of 5 antihypertensive drugs but leaving 234 patients on placebo. Over the ensuing 48 months, the patients practiced the lifestyle modifications as would most patients in routine clinical practice, carefully at first and less stringently later (Fig. 3) . As seen in Fig. 3 , they increased their level of physical activity and reduced their weight, sodium intake and alcohol consumption a moderate amount initially and then began to cut back on their adherence to the regimen so that at the end of the 48 months, they had relatively small changes in the four practices.
Despite the relatively poor adherence to the lifestyle regimen, they achieved an average reduction in blood pressure of -8.6/-8.6 mmHg, accompanied by a decrease in left ventricular mass and an improvement in the HDL: total cholesterol ratio. These benefits, easily obtained, should not be denied to any hypertensive, whether given antihypertensive therapy or not.
Assessment of Overall Cardiovascular Risk
Once the diagnosis is established, the patient's overall cardiovascular risk status should be ascertained in order to decide upon the need for active drug therapy. In former times, at least in the US, the decision was usually based only on the level of blood pressure. However, more and more evidence has documented two facts about the risks of cardiovascular damage from hypertension: first, the risks are almost multiplied by the presence of other major risk factors as shown best by the Framingham Heart Study (13); second, hypertensives have more than twice to 3 times more of the risk factors than do normotensives.
Therefore, all hypertensives should be checked for the other risk factors, usually by simple techniques (Table 5) . A question mark is placed by the use of echocardiography for ascertainment of left ventricular hypertrophy, the measurement of insulin resistance and plasma fibrinogen. Though all of these are proven risk factors, their measurements are either too expensive or not readily available for routine use.
Once the overall risk status is ascertained and knowledge of the degree of target organ damage obtained, a more rational decision can be made about the need for institution of antihypertensive drug therapy. The recent recommendations of an expert committee from New Zealand place this in the most rational context (14). They provide a diagram, based upon the Framingham data, of the likelihood of a major cardiovascular event occurring in the next 10 years, separately for men and women (since women have relatively less likelihood of trouble from any given level of blood pressure), divided into decades, and by various levels of blood pressure (Fig. 4) .
These experts have decided that treatment should be provided only if the risk is 20% or greater of a cardiovascular event over the next 10 years (or if the level of blood pressure is so high, 1701100 mmHg or greater, as to mandate therapy regardless of overall risk status) . They base this decision on the balance between the known benefits of therapy from multiple clinical trials and the known costs of therapy, both financial and on quality of life.
One could argue that these criteria are too conservative, denying therapy to some who would ben- Nonetheless, the concept is correct, even if the criteria are too conservative. Perhaps drug therapy should be provided for all with a 10% or greater risk status. But that would markedly increase the number of patients being treated and I am sure the New Zealand experts would persuasively argue that the hard data on costs and benefits do not justify this expansion of therapy to so many who will not benefit from it.
The same argument has been made by Professor John Swales (15). He states:
"There are no absolute standards for identification of high-risk patients, other than to define the point below which treatment would produce net h arm as a result of adverse drug effects outweighing benefit. Moreover, there are no trial data to indicate where this point occurs, but it is clearly influenced by age, sex, and the presence of other cardiovascular risk-factors. The most rational approach was adopted in the New Zealand guidelines, which use as a starting point a value judgment about absolute risk. The decision was that an absolute risk of cardiovascular disease of 20% over 10 years was significant and justified treatment " "No other guidelines attempt the rigorous definition of risk essayed by the New Zealand group. All guidelines implicitly recognise the need to focus treatment on individuals at higher absolute risk to avoid the necessity of treating large populations for small benefit. The precise definition of 'higher risk' is left open, although it clearly reflects the putative benefits set against the social costs of treating large populations, which in turn reflect differences in health care systems and divergent expectations." Professor Swales also reviews some of the data upon which the New Zealand experts based their decision . He states:
"Because blood pressures are distributed in a unimodal fashion, there is an exponential increase in patients eligible for treatment as the threshold is lowered. In the screening programme for the Hypertension Detection and Followup Program (HDFP), for example, although 8.4% of the population had a diastolic blood pressure > 100 mmHg, 25.3% had a diastolic blood pressure >_90 mmHg. More than 20% of adults in some populations are already receiving antihypertensive drugs, and in some elderly groups this figure exceeds 50%. The individual benefits associated with lowering the threshold for drug treatment are illustrated in the Medical Research Council (MRC) study. Whilst 333 patients with an entry blood pressure in the 105-109 range require treatment for 1 year to prevent one stroke, the figure rises to 666 patients with a blood pressure of 100 mmHg or more, and to 2,000 for those with a diastolic blood pressure of 95 or more." Therefore, the criteria set forth by the New Zealand group should be carefully considered as a more rational way to decide upon the individual patient's need for institution of active drug therapy.
The Choice of Initial Therapy Once the decision is made to treat, the practitioner must decide which drug to use. This choice has changed very dramatically in the US over the past few years, with a progressive fall in the use of diuretics and beta-blockers and marked rises in the use of calcium entry blockers (now the most popular drugs used to treat hypertension) and angiotensin converting enzyme (ACE) inhibitors (Fig. 5) .
Despite these changes in practice, the 1993 Joint National Committee report recommends that preference be given to diuretics and beta-blockers as the initial choice of therapy (10) (Fig. 6) . The reasons for this is stated:
"Because diuretics and ,9-blockers are the only classes of drugs that have been used in long-term controlled clinical trials and shown to reduce morbidity and mortality, they are recommended as first-choice agents unless they are contraindicated or unacceptable, or unless there are special indications for other agents."
The fact that only diuretics and beta-blockers have been shown to reduce overall mortality is simply because they are the only types of drugs used in the many clinical trials performed over the past 20 years, with the exception of some of the earliest trials which used reserpine or methyldopa. None of the trials used alpha-blockers, ACE inhibitors, or calcium entry blockers for the obvious reason that they were not available when these trials were being planned. Moreover, other than for 3 trials in the elderly completed in 1991-2 (which also used diuretics and beta-blockers), no large scale trials were performed for almost a decade. Only now are trials b eing begun utilizing the newer types of drugs but their results will not be available for 6 to 10 years. Therefore, the JNC-5 statement will stand for the next decade. In the meantime, however, the end of that statement should be recognized as a clear indication that the use of the still untested, newer bring out hypertension in those with the genetic predisposition, including diabetes mellitus, dyslipidemia, alcohol abuse and gout. Others of these conditions are purely coincidental to the older age of most hypertensives, such as benign prostatic hypertrophy. Whatever the reason for the frequent presence of other conditions in hypertensive patients, many of these conditions can be improved by certain types of antihypertensive drugs, while others may be worsened (Table 6 ). In this table, preferred drugs ( + +) are those which should also help the concomitant condition. A good example is an ACE inhibitor in a diabetic with nephropathy. Drugs which are acceptable (+) will likely do less for the concomitant condition but should not be detrimental. An example is the use of an alpha-blocker in such a patient since it may improve insulin sensitivity and counter some of the dyslipidemia frequently found in diabetics but there is no supporting evidence for its ability to slow the progress of diabetic nephropathy.
On the other hand, some drugs are not usually recommended ( +1-) because they may be less effective in the presence of the concomitant condition. An example is a beta-blocker in an elderly black patient. And lastly, in some situations certain drugs are contraindicated ( -) . An example is a beta-blocker in a patient with asthma.
I believe the guidelines shown in Table 6 are reasonable, since they are based on large amounts of clinical experience and since they aim at providing the greatest benefits to the hypertensive patient while avoiding major adverse effects on concomitant conditions. If they are followed, some of the inequities in the costs of medications will be overcome. Although generic diuretics and beta-blockers will continue to be less expensive for some time, the successful treatment of hypertension and congestive heart failure with an ACE inhibitor or the relief of the symptoms of prostatism in an elderly hypertensive with an alpha-blocker will, in fact, save costs There remains, however, the question as to what "control" means . In most of the expert committee recommendations, control is taken as a blood pressure below 140/90. However, some recommend even lower pressures, even to 120/80 or lower if the patient has no obvious complaints related to too great a fall in blood pressure. The need for more aggressive control, below 140/90, has been raised particularly for diabetics with nephropathy, whose course has been improved by ACE inhibitors even if the blood pressure is normal and is lowered further (16).
However, a J curve of increasing mortality when diastolic pressures are lowered below 85 mmHg has been described and documented, particularly in patients with underlying coronary disease (17, 18) . Most of the initial data showing a J curve were retrospective but two prospective studies have confirmed the process (19, 20) . Although there are many who doubt the validity of this observation (15), I believe the pathophysiological basis for worsening coronary perfusion exists and that the data are so uniform that they demand attention. Until (and if) the currently ongoing Hypertension Optimal Treatment Trial (21) disproves the existence of a J curve, I believe prudence dictates that the goal of antihypertensive therapy for most patients be no lower than 130/85 mmHg. In the elderly with predominately systolic hypertension, the goal should probably be a systolic pressure no lower than 140 mmHg.
The Potential for Prevention
The last clinical issue to be addressed is the most important:
can hypertension be prevented. The answer remains uncertain but the evidence continues to increase in breadth and depth. Perhaps the most encouraging evidence comes not from a trial of prevention but from the previously described TOMHS trial (12). The 902 patients in this study had very mild hypertension, their baseline blood pressure averaging 140.4/90.5 mmHg. Recall that the relatively small changes in their lifestyle resulted in a reduction of their blood pressure by -8.6/-8.6 mmHg so that at the end of the 48 months they were in the normotensive range. It may be inappropriate to project these 4 year data to a longer time but the temptation is obvious and not illogical.
